A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.

A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02. Clin Cancer Res. 2014 Dec 15; 20(24):6379-88.

View in: PubMed

subject areas

Aged
Aged, 80 and over
Androgen Antagonists
Antineoplastic Agents, Hormonal
Biomarkers, Tumor
Clinical Trials, Phase III as Topic
Humans
Male
Middle Aged
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Prostatic Neoplasms
Proton Therapy
Treatment Outcome

authors with profiles

James J. Dignam